Ligand Pharma (LGND) Tops Q2 EPS by 60c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $262.17 -4.62%
EPS Growth %: +25.6%
Financial Fact:
Weighted average number of common shares - basic: 20.89M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +25.6%
Financial Fact:
Weighted average number of common shares - basic: 20.89M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.03, $0.60 better than the analyst estimate of $0.43. Revenue for the quarter came in at $57.4 million versus the consensus estimate of $37.73 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Worried the AI trade has gone too far? Evercore likes these 4 stocks
- AeroVironment restates quarterly financials, citing $89M goodwill error
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
